ARCA biopharma grants options to 7 non-employee directors; stockholders re-elect two directors at annual meeting

Oruka Therapeutics, Inc.

Board granted options to purchase 6,000 shares each to 7 non-employee directors at $1.64 per share, vesting monthly over 12 months.
Stockholders re-elected Michael Bristow (6,952,545 for) and Robert Conway (6,758,409 for) as directors for three-year terms.
Ratified KPMG LLP as independent auditor for FY2023 with 10,286,650 for, 263,929 against, 68,141 abstain.
Advisory say-on-pay resolution approved: 6,548,473 for, 1,472,454 against, 19,941 abstain.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2024-01-30 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-01-30

Exact text from the filing

Nominee For Withheld Broker Non-Votes Dr. Michael R. Bristow 6,952,545 1,088,323 2,577,852 Mr. Robert E. Conway 6,758,409 1,282,459 2,577,852

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Oruka Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-30 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2024-01-30

Exact text from the filing

For Against Abstentions Broker Non-Votes 6,548,473 1,472,454 19,941 2,577,852

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2024-01-30 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-01-30

Exact text from the filing

For Against Abstentions Broker Non-Votes 10,286,650 263,929 68,141 —

View on SEC.gov

566 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Oruka Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-009397

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.